New combo aims to cut hormone therapy in prostate cancer
NCT ID NCT06574880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is testing whether combining the drug Pluvicto with precise radiation (SBRT) can lower the chance of cancer returning in men with locally advanced prostate cancer, while also reducing the need for long-term hormone therapy. About 45 participants will receive one to three doses of Pluvicto along with five radiation sessions. The study is in early phases, so the main goals are to find the safest dose and see how long men can go without needing hormone therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pluvicto (Lu-PSMA-617) and stereotactic body radiotherapy (SBRT)
What this could lead to
If successful, this could offer a way to treat locally advanced prostate cancer with less need for long-term hormone therapy, potentially preserving quality of life.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply broadly. The combination of radiation and Pluvicto may cause side effects, and it is not yet known if it will effectively prevent cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States